Human melanoma cells growth arrest irreversibly, lose tumorigenic potential and terminally dierentiate after treatment with a combination of ®broblast interferon (IFN-b) and the protein kinase C activator mezerein (MEZ). Applying subtraction hybridization to this model dierentiation system permitted cloning of melanoma dierentiation associated gene-7, mda-7. Expression of mda-7 inversely correlates with melanoma development and progression, with elevated expression in normal melanocytes and nevi and increasingly reduced expression in radial growth phase, vertical growth phase and metastatic melanoma. When expressed by means of a replication incompetent adenovirus (Ad.mda-7) growth of melanoma, but not normal early passage or immortal human melanocytes, is dramatically suppressed and cells undergo programmed cell death (apoptosis). Infection of metastatic melanoma cells with Ad.mda-7 results in an increase in cells in the G 2 /M phase of the cell cycle and changes in the ratio of pro-apoptotic (BAX, BAK) to anti-apoptotic (BCL-2, BCL-XL) proteins. Ad.mda-7 infection results in a temporal increase in mda-7 mRNA and intracellular MDA-7 protein in most of the melanocyte/melanoma cell lines and secretion of MDA-7 protein is readily detected following Ad.mda-7 infection of both melanocytes and melanoma cells. The present studies document a dierential response of melanocytes versus melanoma cells to ectopic expression of mda-7 and support future applications of mda-7 for the genebased therapy of metastatic melanoma.
Introduction
A useful experimental model for de®ning the genetic and biochemical changes underlying tumor progression is metastatic human melanoma (Herlyn, 1990; Lu and Kerbel, 1994; Leszczyniecka et al., 2001) . Of the numerous types of cancer developing in North American populations, melanoma is increasing at the fastest rate and it is estimated that as many as one in 75 currently born Caucasian children may eventually develop super®cial spreading type melanoma (Clark, 1991; Armstrong and Kricker, 1994) . Although melanoma is curable at early stages, surgical and chemotherapeutic interventions are virtually ineective in preventing metastatic disease and death in patients with advanced stages of malignant melanoma. These ®ndings underscore the need for improved therapeutic approaches to more ecaciously treat patients with metastatic melanoma.
Development of malignant melanoma in humans, with the exception of nodular type melanoma, may involve a series of sequential alterations in the evolving tumor cells (Herlyn, 1990; Clark, 1991; Armstrong and Kricker, 1994; Lu and Kerbel, 1994; Leszczyniecka et al., 2001) . Although several models of progression are possible, a proposed scheme for cutaneous melanoma development consists of the conversion of a normal melanocyte into a common acquired melanocytic nevus (mole), followed by the development of a dysplastic nevus, a radial growth phase (RGP) primary melanoma, a vertical growth phase (VGP) primary melanoma and ultimately a metastatic melanoma (Herlyn, 1990; Clark, 1991; Armstrong and Kricker, 1994; Lu and Kerbel, 1994; Leszczyniecka et al., 2001) . Although primary melanoma is readily treatable, even during the VGP if the lesion is 40.76-mm thick, currently employed techniques are minimally eective (520% survival) in preventing metastatic spread and morbidity in patients with VGP lesions of 44.0-mm thickness.
Cancer progression has been extensively studied in the context of human melanocytes, nevi, primary melanomas and metastatic melanomas (Herlyn, 1990; Clark, 1991; Armstrong and Kricker, 1994; Lu and Kerbel, 1994 ; Leszczyniecka et al., 2001) . Tumor progression in melanocytes correlates with aberrant melanocytic dierentiation (Herlyn, 1990; Leszczyniecka et al., 2001; Yang et al., 2001) . Chemical induction of terminal dierentiation in tumor cells represents a useful approach for reversing the malignant properties of tumor cells by inducing terminal dierentiation, a process termed dierentiation therapy' (Jiang et al., 1994; Waxman, 1995) . The combination of IFN-b plus MEZ reprograms metastatic human melanoma cells to undergo a loss of cancerous potential and terminally dierentiate, i.e., cells retain viability but they permanently exit the cell cycle (Fisher et al., 1985; Jiang et al., , 1995c . These observations provide the basis for the aberrant dierentiation/modi®ed gene expression model of human melanoma development Jiang et al., 1994) . This scheme predicts that in many cellular contexts the genetic elements necessary to control tumor growth are present, but expression (regulated transcriptionally and/or posttranscriptionally) occurs at a level below the threshold required to elicit a physiological response Jiang et al., 1994; Madireddi et al., 2000a,b) . However, when exposed to an appropriate inducer the necessary repertoire of gene changes controlling growth and inducing dierentiation in cancer cells are activated Jiang et al., 1994 Jiang et al., , 1995b Madireddi et al., 2000a,b; Huang et al., 1999a,b) .
Subtraction hybridization identi®ed a novel melanoma dierentiation associated (mda) gene, mda-7, that appears to ®t the anticipated pro®le of a negative regulator of human melanoma growth and progression (Jiang et al., 1995a) . Mda-7 expression increases in growth arrested and dierentiation inducer treated human melanoma cells in a p53-independent manner (Jiang et al., 1995a) . The de novo level of mda-7 is higher in normal melanocytes vs. metastatic human melanoma cells and in less progressed vs. progressed early vertical growth phase (VGP) primary human melanoma cells (Jiang et al., 1995a) . Moreover, mda-7 is a ubiquitous inhibitor of growth in diverse human cancers, but not in normal human epithelial, endothelial or ®broblast cells (Jiang et al., 1996; Su et al., 1998; Madireddi et al., 2000c; Saeki et al., 2000; Mhashilkar et al., 2001 ). This particular property of mda-7 suggests that this gene may have direct translational potential for the gene-based therapy of cancer (Madireddi et al., 2000c; Mhashilkar et al., 2001) .
The present studies were designed to analyse the eects of ectopic expression of mda-7, administered by means of a replication-incompetent adenovirus, Ad.mda-7, on the growth, cell cycle kinetics and survival of normal, early passage and human immortal, melanocytes and nonmetastatic and metastatic human melanoma cells. In normal melanocytes, growth, cell cycle progression and survival remain unaltered following infection with Ad.mda-7. In contrast, Ad.mda-7 induces growth suppression, accumulation of cells in the G 2 /M phase of the cell cycle and apoptosis in melanoma cells, which correlates with an alteration in the ratio of pro-apoptotic to anti-apoptotic proteins. These results provide support for the hypothesis that mda-7 may function as an endogenous inhibitor of melanoma growth and progression and forced expression of mda-7 in the context of melanoma cells oers promise for the gene-based therapy of this neuroectodermal tumor.
Results
Effect of adenovirus administered mda-7, wild type p53 and p21 on the growth of normal melanocytes and melanoma cells
The eect of Ad.mda-7 on the growth of normal SV40-immortalized human melanocytes (FM516), a radial growth phase primary human melanoma (WM35) and metastatic human melanoma (HO-1, FO-1 and MeWo) cells is shown in Figure 1 . For comparison, the eects of Ad.vec (control adenovirus lacking the mda-7 gene insert) and adenoviruses expressing growth suppressing/apoptosis inducing genes, wild-type p53 (Ad.p53) or the cell cycle kinase inhibitor p21 (Ad.p21) (CIP-1, mda-6, SDI-1, WAF-1) el Deiry et al., 1993; Harper et al., 1993; Noda et al., 1994; Jiang et al., 1995b,c) were determined. Previous studies demonstrate that Ad.p53 induces growth suppression and apoptosis in murine (B16) and human (SK-MEL-24) melanoma cells, both in vitro and in vivo in nude mice (Cirielli et al., 1995) . Similarly, infection of UM-316 human melanoma cells with an adenoviral vector expressing p21 (mda-6) results in induction of a more dierentiated phenotype and growth is suppressed both in vitro and in vivo in nude mice .
In the case of FM516 melanocytes, a minimal antiproliferative eect (410% inhibition, 7 days postinfection) was apparent with Ad.mda-7, whereas Ad.p53 and Ad.p21 inhibited growth by *24% and *16% 7 days post-infection, respectively (Figure 1) . No signi®cant growth inhibition was apparent in normal human melanocytes (NHuMEL) following infection with Ad.mda-7 (data not shown). In contrast, Ad.mda-7, Ad.p53 and Ad.p21 inhibited the growth of WM35 and all three metastatic melanoma cell lines (Figure 1 ). In general, the magnitude of the growth inhibitory eect of the three viruses was similar in the dierent melanoma cell lines, with inhibition being readily apparent by 4 days post-infection with little subsequent recovery by day 7 (inhibition ranging between *60 and 480% versus untreated control and Ad.vec infected cultures). These studies document that Ad.mda-7 selectively induces growth suppression in melanoma cells, in a similar manner as Ad.p53 and Ad.p21, without signi®cantly modifying growth in normal melanocytes.
Temporal expression of mda-7 in normal human melanocytes and melanoma cells following Ad.mda-7 infection Mda-7 is expressed de novo in early passage normal and immortal FM516 melanocytes (Jiang et al., 1995a; Ekmekcioglu et al., 2001; Huang et al., 2001) . In contrast, mda-7 is not detected, or is present at reduced levels, in most metastatic melanoma cell lines and in metastatic melanoma lesions from patients (Jiang et al., 1995a; Ekmekcioglu et al., 2001; Huang et al., 2001) . Previous studies document that treatment with IFNb+MEZ for 24 h results in growth suppression and induction or enhanced mda-7 mRNA expression in vitro in both primary and metastatic human melanoma cell lines (Jiang et al., 1995a; Huang et al., 2001) . These results indicate an inverse relationship between expression of mda-7 and melanoma growth and progression, suggesting that mda-7 may function as a negative regulator of both processes in melanoma cells (Jiang et al., 1995a; Huang et al., 2001) .
Infection of melanocytes and melanoma cells with 100 p.f.u./cell of Ad.mda-7 results in elevated (FM516) or induced (melanoma cells) expression of mda-7 mRNA by 6 ± 12 h post-infection (Figure 2 ). In FM516, WM35 and HO-1 cells, expression reaches a plateau by 24 ± 48 h, whereas temporal increases in mda-7 mRNA are apparent in MeWo and FO-1 cells when assayed over a 96 h period following infection with Ad.mda-7. Dose-response studies indicate that infection of the dierent cell lines with as little as 1 p.f.u./cell of Ad.mda-7 results in the induction (melanoma cell lines) or enhanced expression (FM516) of mda-7 mRNA by 24 h (Figure 2 ). In the case of FM516 cells, maximum mda-7 expression was apparent with 10 p.f.u./cell, with no signi®cant increase occurring following infection with 50 or 100 p.f.u./cell of Ad.mda-7. In the melanoma cell lines, a dose-dependent increase in mda-7 mRNA was apparent with increasing m.o.i.'s (from 1 ± 100 p.f.u./ cell) of Ad.mda-7. The maximum levels of mda-7 mRNA obtained following infection with 50 or 100 p.f.u./cell of Ad.mda-7 were greatest in the metastatic melanoma cells ( Figure 2 and Table 1 ). In contrast, lower levels of mda-7 mRNA were apparent in FM516 and WM35 cells after infection with 50 or 100 p.f.u./cell of Ad.mda-7. Infection with control Ad.vec. did not change the mda-7 mRNA expression levels in normal melanocytes or in melanoma cells when tested at 100 p.f.u./cell (data not shown).
To exclude the possibility that the dierential levels of mda-7 mRNA in the various cell lines following infection with Ad.mda-7 simply re¯ect dierences in adenovirus uptake, FACS analysis was performed to monitor coxsackie-adenovirus receptors (CAR), which mediate adenovirus attachment and uptake in cells (Hidaka et al., 1999; Li et al., 1999; Pearson et al., 1999; Fechner et al., 2000) (Table 2 ). This analysis indicated the following order of CAR receptors, FO-1 4HO-1 4WM35 5MeWo 4FM516. Based on these results, it is apparent that a simple correlation does not exist between the relative number of CAR receptors and mda-7 expression following Ad.mda-7 infection in these melanocytes/melanoma cell lines. It is likely therefore that the varied response observed in these cells re¯ects dierential regulation of transgene expression in these cells after viral entry.
Analysis of intracellular MDA-7 protein levels by SDS ± PAGE after Ad.mda-7 infection (100 p.f.u./cell) indicates a temporal increase in protein in most of the cell types, with the exception of FM516 (in which protein levels remain relatively constant between 18 and 96 h post-infection) (Figure 3) . A dose-dependent increase in MDA-7 protein is also observed in the dierent cell types following infection with increasing m.o.i.'s of Ad.mda-7 (unpublished data). The mda-7 cDNA contains a classical secretory motif (Jiang et al., 1995a; Huang et al., 2001; Mhashilkar et al., 2001) and secretion of MDA-7 protein following Ad.mda-7 infection of H1299 lung carcinoma cells has been documented . Based on these ®ndings, experiments were performed to determine if MDA-7 protein is secreted from melanocytes and/or melanoma cells following infection with Ad.mda-7. The dierent cell types were infected with various m.o.i.'s of Ad.mda-7 of Ad.vec (100, 500 or 1000 p.f.u./cell) and cell lysates and culture supernatants were evaluated for MDA-7 protein by Western blotting (Figures 3 and 4) . MDA-7 protein was detected in the supernatants of Ad.mda-7 infected normal melanocytes (FM516) and melanoma cells (WM35, HO-1, FO-1 and MeWo) ( Figure 4 and data not shown). The relative sizes of the protein species identi®ed by Western blotting using MDA-7 polyclonal antibody varied for the dierent cell types, including proteins that were larger or of similar size to those found intracellularly ( Figure 4 and data not shown). These results suggest that the MDA-7 protein may be processed dierently in the various cell types prior to secretion, which could re¯ect variations in the extent of phosphorylation and/or glycosylation of the secreted proteins.
Mda-7 induces cell cycle changes and apoptosis selectively in melanoma cells
Previous studies demonstrate that Ad.mda-7 induces apoptosis in several human cancer cell types, including carinomas of the breast, cervix, colon, lung and prostate, without producing changes in growth or causing apoptosis in normal cells, including primary human mammary epithelial, endothelial and ®broblast cells (Jiang et al., 1996; Su et al., 1998; Madireddi et al., 2000c; Saeki et al., 2000; Mhashilkar et al., 2001) . In addition, a dose-dependent elevation of cells in the G 2 /M phase of the cell cycle occurs in T47D breast carcinoma cells infected with Ad.mda-7 . Based on these observations, experiments were performed to determine if mda-7 selectively induces growth suppression in human melanoma cells Figure 2 Temporal and multiplicity of infection eects on mda-7 expression in normal melanocytes and melanoma cells after infection with Ad.mda-7. For the time course studies, the indicated cell type was infected with 100 p.f.u./cell of Ad.mda-7 and total RNA was isolated at the times indicated (hpi stands for`hours post infection') and analysed by Northern blotting. For the multiplicity of infection (m.o.i.) study, cells were infected with the indicated moi and total RNA was extracted 24 h postinfection and analysed by Northern blotting. Ten mg of each RNA sample was analysed by Northern blotting. Blots were probed with a random-primed 32 P-labeled mda-7 cDNA, the blots were stripped and then reprobed with a random-primed 32 P-labeled gapdh cDNA probe. Blots were exposed for autoradiography Logarithmically growing cells were resuspended and stained with anti-CAR monoclonal antibody. After washing with PBS, cells were stained with FITC-labeled anti-mouse goat IgG, washed with PBS and analysed by FACS. Characterization of peak shift was determined using ratios from FACS histograms and the Kolmogorov-Smirnov (K-S) test as described in Young (1977) . D value represents the dierences between the two curves; higher numbers re¯ect enhanced binding and increased CAR receptors Previous studies con®rm that changes in the levels of BAX and the ratio of BAX to BCL-2 proteins may be important mediators in the induction of apoptosis in breast cancer cells by mda-7 (Su et al., 1998; Madireddi et al., 2000c) . To determine if these apoptosis associated molecules or additional anti-apoptotic (BCL-XL) or proapoptotic (BAK) proteins contribute to programmed cell death in melanoma cells, the levels of the various proteins were determined by Western blotting 6 ± 96 h postinfection with Ad.mda-7 (Figure 6 ). In the case of FM516 cells growth was not signi®cantly altered by either virus and these cells did not undergo apoptosis and only minor changes in BCL-2 and BCL-XL protein (1.7-and 1.2-fold reduction, respectively) and in BAX and BAK protein (1.2-fold upregulation and no change in expression, respectively) occurred 96 h after infection with 100 p.f.u./cell of Ad.Mda-7 ( Figure 6 and Table 3) . Similarly, no consistent modi®cations in these proteins were apparent in NHuMEL infected with Ad.mda-7 (Figure 6 ). In the melanoma cells, variable changes were observed in BCL-2 protein levels after Ad.mda-7 infection, whereas consistent temporal decreases were apparent in all four melanoma cell lines with respect to Figure 3 Determination of intracellular MDA-7 protein in human normal early passage and immortal melanocytes and melanoma cells after infection with Ad.mda-7. Cells were infected with Ad.vec or Ad.mda-7 as described in Materials and methods, and protein samples were collected in RIPA buer at dierent time points. Samples (30 mg of total protein) were run on 12% SDS ± PAGE, transferred to Immobilon P PVDF membranes and stained with rabbit anti MDA-7 antibody as described. After longer exposures, MDA-7 protein can be detected in untreated and Ad.vec infected NHuMEL cells (data not shown) BCL-XL protein levels. A 1.2-, 3-and 3.5-fold downregulation in BCL-2 was apparent in WM35, MeWo and FO-1 cells, respectively, and no change in BCL-2 was evident in HO-1 cells 96 h post-infection with 100 p.f.u./ cell of Ad.mda-7. In the case of BCL-XL protein, decreases of 9.2-, 6.7-, 3-and 6.5-fold respectively were apparent in WM35, MeWo, HO-1 and FO-1 cells 96 h post-infection with Ad.mda-7 ( Figure 6 and Table 3 ). In the case of BAX and BAK proteins, a maximum upregulation of 1.8-and 2.2-fold were observed in WM35 and HO-1 cells, respectively, 96 h post-infection with Ad.mda-7. These results suggest that decreases in the levels of anti-apoptotic (BCL-2/BCL-XL) versus proapoptotic (BAX/BAK) proteins resulting from infection with Ad.mda-7 may trigger apoptosis selectively in melanoma cells.
Discussion
The cancer speci®c growth suppressing and apoptosis inducing gene mda-7 was cloned in the context of melanoma cell dierentiation (Jiang et al., 1995a) . Although constitutively expressed in normal melanocytes, the majority of melanoma cells, including RGP, VGP and metastatic melanomas, display reduced or in the case of metastatic melanomas no mda-7 expression (Jiang et al., 1995a; Ekmekcioglu et al., 2001; Huang et al., 2001) . However, when melanoma cells are treated with IFN-b+MEZ, which induce an irreversible loss of growth potential and terminal dierentiation, mda-7 expression ensues (Jiang et al., 1995a; Madireddi et al., 2000a,b; Huang et al., 2001) . These results suggest a correlation between mda-7 expression and reversion in the cancer phenotype of melanoma cells, including induction of terminal dierentiation and terminal growth arrest (Jiang et al., 1994 (Jiang et al., , 1995a . The present studies were designed to expand on these observations and determine the eect of ectopic expression of mda-7, administered by Ad (Ad.mda-7), on growth, cell cycle kinetics and survival of normal melanocytes and melanoma cells. We demonstrate that Ad.mda-7 does not alter cell growth, cell cycle kinetics or survival in normal early passage and immortal human melanocytes, whereas growth is suppressed, cell cycle is modi®ed resulting in an increase in cells in the G 2 /M phase and apoptosis is selectively induced in human melanoma cells. These results support the concept that mda-7 is a negative regulator of cell growth and progression in melanoma cells and this gene may ®nd utility in the gene-based therapy of metastatic melanoma.
When produced at potentially physiological levels in melanoma cells by means of a plasmid expression vector, mda-7 induces growth suppression without promoting terminal dierentiation (Jiang et al., 1995a) . Similarly, mda-7 transfection of a spectrum of tumor cell types induces growth suppression, without modifying proliferation in normal ®broblast or epithelial cells (Jiang et al., 1996) . In contrast, supraphysiological levels of MDA-7 resulting from infection with a replication-incompetent adenovirus expressing mda-7 (Ad.mda-7) causes growth suppression and induction of apoptosis in a variety of human tumor cells (Su et al., 1998; Madireddi et al., 2000c; Saeki et al., 2000; Mhashilkar et al., 2001) . However, Ad.mda-7 still induces no overt changes in cellular physiology in normal cells. The mechanism by which Ad.mda-7 selectively induces apoptosis in cancer versus normal cells is not presently known but is actively being investigated.
When ®rst isolated and characterized, bioinformatic analysis of MDA-7 suggested that this was a novel cDNA, without overt homology to sequences reported in databases and lacking obvious identi®able structural characteristics or motifs at the peptide level (Jiang et al., 1994 (Jiang et al., , 1995a (Jiang et al., , 1996 . Current data suggest that mda-7 is a member of the four-helix bundle family of cytokine molecules (Chaiken and Williams, 1996; Kotenko et al., 2001; Huang et al., 2001) with greatest homology to the IL-10 subfamily, which now includes IL-19, IL-TIF, AK-155 and IL-20 (Gallagher et al., 2000; Zhang et al., 2000; Xie et al., 2000; . Although the extent of amino acid homology between the various members of the IL-10 family is not extensive, IL-10 and mda-7 share 520% sequence identity, the presence of an IL-10 signature sequence, a 49 amino acid N-terminal signal peptide and location in the human genome on chromosome Figure 4 Determination of intracellular and secreted MDA-7 protein in human normal immortal melanocytes and in a metastatic melanoma cell line after infection with Ad.mda-7. Normal human immortal melanocytes (FM516) and MeWo metastatic human melanoma cells were infected with dierent m.o.i.'s of Ad.vec and Ad.mda-7, and 24 h after infection, cell lysates (lys) and culture supernatants (s25 and s50 correspond to 25 and 50 ml of supernatant, respectively) were evaluated for MDA-7 protein by Western blotting, as described in the Results. The 25 ml supernatant sample for MeWo cells infected with 1000 p.f.u./cell of Ad.mda-7 is not shown in this experiment locus 1q32 in an apparent cytokine cluster, with linkage to other family members such as IL-10, IL-19 and IL-20, reinforce the idea that mda-7 is a member of the IL-10 gene family (Huang et al., 2001 ). The present data demonstrates that Ad.mda-7 infection of normal immortal melanocytes and melanoma cells results in secretion of MDA-7 (Figure 4) . Based on the apparent mechanism of action of IL-10 and other members of this gene family, it is possible that the processed secreted MDA-7 interacts with a receptor on the surface of cells, thereby eliciting its biological eects. Support for this hypothesis has recently been provided by studies documenting that MDA-7 binds to the previously described IL-20R complex resulting in STAT phosphorylation and activation of a minimal promoter that includes STAT binding sites (Dumoutier et al., 2001) . In these contexts, the mechanism for the dierential response between cancer and normal cells to mda-7 could involve dierences in the number, types, and/or anity of receptor(s) and/or signaling pathways induced post-receptor binding. Experiments are currently focusing on this important area of investigation to obtain further insights into the dierential response of cancer cells to this secreted cytokine. Apoptosis is controlled by a balance between proteins that promote and proteins that inhibit apoptosis (Adams and Cory, 1998; Evan and Littlewood, 1998; Green and Reed, 1998; Thornberry and Lazebnik, 1998; Wilson, 1998) . In human breast cancer, and additional cancer subtypes, induction of apoptosis by mda-7 correlates with an elevation in the levels of the pro-apoptotic protein BAX and a decrease in the ratio of BCL-2 to BAX, thereby switching the balance within these cancer cells toward apoptosis (Su et al., 1998; Saeki et al., 2000; Figure 6 Determination of BCL-2, BCL-XL, BAX, BAK and EF-1a protein levels in normal early passage primary and immortal melanocytes and in melanoma cells as a consequence of infection with Ad.mda-7. Cells were infected with 100 p.f.u./cell of Ad.vec or Ad.mda-7 as described in Materials and methods, and protein lysates were prepared at the speci®ed time points. Samples of 50 mg of total protein were run on 12% SDS ± PAGE, transferred to a PVDF membrane and stained with dierent antibodies as described in Materials and methods BCL-family proteins expression, as determined by Western blot analysis, was quantitatively analysed via laser-scanning densitometry using NIH Image Version 1.61 software. All results were calculated as a percentage of protein expression in Ad.mda-7 versus Ad.vec infected cells 96 h after infection Madireddi et al., 2000c; Mhashilkar et al., 2001) . In most of the melanomas analysed in the present study. Ad.mda-7 only modestly changed the levels of BAX and BAK proteins, which are present de novo in the uninfected control and Ad.vec infected cells (Figure 6 ), whereas an *3-to *9.2-fold reduction in BCL-XL is apparent in the various melanoma cells 96 h postAd.mda-7 infection. In the normal immortal FM516 cells, the levels of BCL-XL proteins are not signi®cantly changed, displaying only an *1.2-fold decrease. With respect to BCL-2 protein, an *3 to *3.5-fold decrease is apparent in MeWo and FO-1 cells 96 h post-infection with Ad.mda-7, whereas no change occurs in Ad.mda-7 infected HO-1 and only an *1.2-fold decrease is apparent in WM35 cells. These ®ndings suggest that decreases in the ratio of antiapoptotic (BCL-2 and BCL-XL) proteins to proapoptotic (BAX and BAK) may be the major determinant of induction of apoptosis in human melanoma cells following infection with Ad.mda-7.
Further studies are required to de®ne the mechanism by which mda-7 selectively alters the levels of BCL-XL and BCL-2 proteins in melanoma cells and the functional signi®cance of this down regulation to the apoptotic process. In summary, the present studies demonstrate selective eects of mda-7 on growth, cell cycle and survival of melanoma cells, which are not apparent in normal melanocytes. We further document that MDA-7 protein is secreted by both normal melanocytes and melanoma cells following infection with Ad.mda-7 and induction of apoptosis in melanoma cells by Ad.mda-7 correlates with decreases in the levels of the anti-apoptotic proteins, BCL-XL and to a lesser extent BCL-2. The selective eect of mda-7 on melanoma versus normal melanocytes provides support for the potential use of Ad.mda-7 for the therapy of melanoma. Moreover, since mda-7 appears to function as a secreted cancer speci®c growth suppressing and apoptosis-inducing cytokine, it is possible that the therapeutic properties of mda-7 may extend past the primary tumor cells exposed to this gene. Studies are presently in progress to test this hypothesis, which if validated would have signi®cant implications for therapeutic applications of this novel cancer growth suppressing and apoptosis-inducing gene.
Materials and methods

Cell lines and culture conditions
HO-1 and MeWo are established human melanotic melanoma cell lines and FO-1 is an established human amelanotic melanoma cell line isolated from separate patient-derived metastatic lesions (Giovanella et al., 1976; Kerbel et al., 1994; Fisher et al., 1985; Graham et al., 1991) . WM35 was derived from an RGP primary human melanoma (Herlyn, 1990) . FM516-SV (FM516) is a normal human melanocyte culture immortalized by the SV40 T-antigen gene (Melber et al., 1989) . HO-1, MeWo, FO-1, WM35 and FM516 cell lines were grown in Dulbecco's modi®ed Eagle's medium supplemented with 10% fetal bovine serum (DMEM-10) at 378C in a 95% air 5% CO 2 humidi®ed incubator. Normal early passage human foreskin melanocytes (NHuMEL) were obtained from BioWhittaker and were grown as described by the supplier.
Virus construction, plaque assays and virus infection protocol
The recombinant replication-defective Ad.mda-7 virus was created in two steps as described previously (Su et al., 1998) . Brie¯y, the coding region of the mda-7 gene was cloned into a modi®ed Ad expression vector pAd.CMV (Falck-Pedersen et al., 1994) . This vector contains, in order, the ®rst 355 bp from the left end of the Ad genome, the cytomegalovirus immediate early promoter, DNA encoding splice donor and acceptor sites, the coding region of the mda-7 cDNA, DNA encoding a polyA signal sequence from the b-globin gene, and *3 kbp of adenovirus sequence extending from within the E1B coding region. This arrangement allows high-level expression of the cloned sequence by the cytomegalovirus immediate early gene promoter, and appropriate RNA processing (Falck-Pedersen et al., 1994) . The recombinant virus was created in vivo in 293 cells (Graham et al., 1977) by homologous recombination between mda-7-containing vector and plasmid JM17, which contains the whole of the Ad genome cloned into a modi®ed version of pBR322 (McGrory et al., 1988) . JM17 gives rise to Ad genomes in vivo but they are too large to package. This constraint is relieved by recombination with the vector to create a packageable genome (McGrory et al., 1988) , containing the mda-7 gene. The recombinant virus is replication defective in human cells except 293 cells, which express adenovirus E1A and E1B. Following transfection of the two plasmids, infectious virus was recovered, the genomes were analysed to con®rm the recombinant structure, and then virus was plaque puri®ed, all by standard procedures (Volkert and Young, 1983) . Stock virus preparations were diluted in DMEM containing 1% fetal bovine serum and inoculated onto cell monolayers at the indicated m.o.i. After 2 h virus adsorption at 378C with rotation every 15 min, the virus inoculum was removed and DMEM-10 was added to the infected monolayer cultures and cells were incubated at 378C for the indicated times.
RNA isolation and Northern blotting assays
Total cellular RNA was isolated by the guanidinium/phenol extraction method and Northern blotting was performed as described (Su et al., 1997) . Fifteen mg of RNA were denatured and electrophoresed in 1.2% agarose gels with 3% formaldehyde, transferred to nylon membranes and hybridized sequentially with 32 P-labeled cDNA probes as described previously (Su et al., 1997 (Su et al., , 1999 . Following hybridization, the ®lters were washed and exposed for autoradiography.
Cell cycle analysis
Cells were trypsinized, washed 26 with PBS and ®xed in 70% ethanol overnight at 7208C. Then cells were washed 26 with PBS, and aliquots of 1610 6 cells were resuspended in 1 ml of PBS containing 1 mg/ml of RNase A and 0.5 mg/ ml of propidium iodide. After 30 min incubation, cells were analysed by¯ow cytometry using a FACScan¯ow cytometer (Becton Dickinson, San Jose, CA, USA).
Annexin-V binding assay
Cells were trypsinized and washed once with complete media. The aliquots of the cells (5610 5 ) were resuspended in complete media (0.5 ml) and stained with FITC-labeled Annexin-V (kit from Oncogene Research Products, Boston, MA, USA) according to the manufacturer's instructions. Propidium iodide (PI) was added to the samples after staining with Annexin-V to exclude late apoptotic and necrotic cells. The FACS assay was performed immediately after staining.
Detection of CAR receptors on the cell surface
Cells were harvested by trypsinization, washed 26 with PBS and stained with 1 : 1000 dilution of monoclonal anti-CAR antibody, for 1 h at 378C. After additional washings with PBS (265 min), cells were stained in the dark for 1 h at 378C with a 1 : 500 dilution of¯uorescein-labeled goat anti-mouse immunoglobulins (BioSource International, Camarillo, CA, USA). After washings with PBS, cells were analysed by¯ow cytometry (5610 5 cells per sample). Unstained cells and cells stained with monoclonal anti-SV40 antibody (Santa Cruz, CA, USA) and with secondary antibody only were used as controls. Two methods were used for semi-quantitation of the results. The shift of FL1 peak was calculated as dierence in peak channels between the control (cells unstained or stained with non-speci®c antibody) and the experimental cells stained with anti-CAR antibody relative to the position of the control cell peak channel. The second method uses the Kolmogorov-Smirnov (K-S) test for overlaid histograms (Young, 1977) . The calculation computes the summation of the overlaid curves and determines the greatest dierence between the summation curves (K-S statistics). D value indicates the greatest dierence between the two curves.
DNA extraction and fragmentation assays
DNA extraction and fragmentation (DNA ladder) assays were performed as previously described (Su et al., 1995) . Brie¯y, 4 days after infection with 100 p.f.u./cell of Ad.vec or Ad.mda-7, cells were collected (both attached, with trypsinization, and¯oating) and placed in lysis buer (10 mm Tris, pH 7.9, 5.0 mm EDTA, 0.1 m NaCl, 0.5% SDS and 1 mg/ml pronase (Sigma)). Cell lysates were incubated at 378C for 2 h and then the lysate was adjusted to 1N by addition of 5N NaCl and stored at 48C overnight. The lysate was centrifuged at 57 0006g for 1 h at 48C and the Hirt supernatant was extracted with phenol and chloroform and precipitated with three volumes of cold EtOH. After RNase treatment (20 mg/ ml), 30 mg were loaded onto a 2% agarose gel and electrophoresed at 25 V for 12 h.
Western blot analysis
Cells were washed 26 with cold PBS and lysed on ice for 30 min in 100 ml of cold RIPA buer (50 mm Tris-HCl (pH 8.0), 150 mm NaCl, 0.1% SDS, 1% NP40, and 0.5% sodium deoxycholate) with freshly added 0.1 mg/ml phenylmethylsulfonyl¯uoride, 1 mm sodium orthovanadate, and 1 mg/ml aprotinin. Cell debris were removed by centrifugation at 14 000 g for 10 min at 48C. Protein concentrations were determined using the Bio-Rad protein assay system (Bio-Rad Laboratories, Richmond, CA, USA). Aliquots of cell extracts containing 20 ± 50 mg of total protein were resolved in 12% SDS ± PAGE and transferred to Immobilon-P PVDF membranes (Millipore Corp., Bedford, MA, USA). Filters were blocked for 1 h at room temperature in Blotto A (5% nonfat milk powder in TBS-T: 10 mm TRIS-HCL (pH 8.0), 150 mm NaCl, 0.05% Tween 20), and then incubated for 1 h at room temperature in Blotto A containing a 1 : 1000 dilution of rabbit anti MDA-7, anti-BCL-2, anti-BCL-XL, anti-BAX, or anti-BAK polyclonal antibodies. After washing in TBS-T buer (365 min, RT), ®lters were incubated for 1 h at room temperature in Blotto A containing a 1 : 10 000 dilution of peroxidase conjugated anti-rabbit secondary antibody (Amersham, Arlington Heights, IL, USA). After washing in TBS-T, ECL was performed according to the manufacturer's recommendation. BCLfamily proteins expression as determined by Western blot analysis was quantitatively analysed via laser-scanning densitometry using NIH Image Version 1.61 software. All results were normalized to EF-1a protein expression.
